What you’ll learn on this page:
- Treating neurologic manifestations has historically been an unmet need in Gaucher disease type 31
Historically, therapies for Gaucher disease type 3 have not been able to cross the blood-brain barrier and remain active within the CNS2,3
While historical therapies can effectively treat Gaucher disease type 3 symptoms related to hepatomegaly, splenomegaly, thrombocytopenia, and anemia, they do not address any of the neurologic manifestations of Gaucher disease type 3.1,2,4
Patients with Gaucher disease type 3 may be vulnerable to progressive neurologic manifestations.2
Frequently asked questions
Interested in learning more?
Definitions: CNS=central nervous system; GCS=glucosylceramide synthase; GL-1=glucosylceramide; lyso-GL-1=glucosylsphingosine.
Relevant pages to view:
Indication
References: 1. Zhong W et al. Acta Neurol Belg. 2024;124(4):1213-1223. 2. Schiffmann R et al. J Inherit Metab Dis. 2020;43(5):1056-1059. 3. Peterschmitt MJ et al. Clin Pharmacol Drug Dev. 2021;10(1):86-98. 4. Grabowski GA et al. The Online Metabolic and Molecular Bases of Inherited Disease. Accessed October 7, 2026. https://ommbid.mhmedical.com/content.aspx?bookid=2709§ionid=225546056 5. Hughes DA et al. GeneReviews® [Internet]. Accessed October 7, 2026. https://www.ncbi.nlm.nih.gov/books/NBK1269/ 6. Donald A et al. Genet Med. 2025;27(9):101502. doi:10.1016/j.gim.2025.101502 7. Cerezyme (imiglucerase). Prescribing Information. Genzyme Corporation, Cambridge, MA. 8. Cerdelga (eliglustat). Prescribing Information. Sanofi. 9. Infilbray (venglustat). Prescribing Information. Genzyme Corporation, Cambridge, MA.
